BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2014;32:663-9. [DOI: 10.1016/j.urolonc.2014.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Guo W, Wang J, Wei H. Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas. Reprod Sci 2016;23:1559-64. [DOI: 10.1177/1933719116648219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Hao H, Chen H, Xie L, Liu H. YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition. Ann Med 2021;53:1170-8. [PMID: 34259106 DOI: 10.1080/07853890.2021.1950920] [Reference Citation Analysis]
3 López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C. Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 2021;247:104329. [PMID: 34298186 DOI: 10.1016/j.jprot.2021.104329] [Reference Citation Analysis]
4 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Reference Citation Analysis]
5 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Thorn AP, Daugaard S, Christensen LH, Christensen IJ, Petersen MM. YKL-40 protein in osteosarcoma tumor tissue. APMIS 2016;124:453-61. [PMID: 26988273 DOI: 10.1111/apm.12524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen HY, Zhou ZY, Luo YL, Luo Q, Fan JT. Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer. Cell Biol Int 2021. [PMID: 34498339 DOI: 10.1002/cbin.11699] [Reference Citation Analysis]
9 Yan J, Shen P, Zheng J, Liu M. Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer. Ann Transl Med 2015;3:354. [PMID: 26807409 DOI: 10.3978/j.issn.2305-5839.2015.11.22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Väänänen T, Kallio J, Vuolteenaho K, Ojala A, Luukkaala T, Hämäläinen M, Tammela T, Kellokumpu-lehtinen P, Moilanen E. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. Scandinavian Journal of Urology 2017;51:367-72. [DOI: 10.1080/21681805.2017.1327885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Cheng D, Sun Y, He H. Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0326-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2016;34:257.e19-24. [DOI: 10.1016/j.urolonc.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Lee Y, Chan T, Tian Y, Liang P, Shiue Y, Chen Y, He H. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder. Urologic Oncology: Seminars and Original Investigations 2019;37:299.e7-299.e18. [DOI: 10.1016/j.urolonc.2019.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]